Let's talk penny stocks. We've all played with them at one time or another, buying shares of a company trading at $1.00 or less because the stock was cheap.
Maybe you read online that a penny stock's price was likely to skyrocket because some big piece of news is going to be announced soon. Maybe your golfing buddy told you to checkout a penny stock and get in before it's too late.
Sometimes penny stock trades work out great and you can book a quick win, but often times the share price stays flat (or even goes down) and the whole trade was a giant waste of time and money.
Trading penny stocks can often feel like gambling, because you're putting up a small amount of money hoping for a big win. You can also lose all your money when you make the wrong bet.
But what if you could take the guess work out of trading penny stocks? Well, there might be a way to do that. We've gathered analyst research reports from every Wall Street firm on every public company whose shares are trading for under $1.00. There are literally thousands of these reports.
Our team sifted through them and found the ten penny stocks that Wall Street's top analysts are nearly universally bullish about. They believe these companies will have incredible upside in the next twelve months.
- Upgrades from Top-Ranked Analysts
- 25 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.9
- Ratings Breakdown
- 26 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $504.36
About Microsoft
Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services.
Read More
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 14 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.6
- Ratings Breakdown
- 9 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $50.08
About Corning
Corning Incorporated engages in the display technologies, optical communications, environmental technologies, specialty materials, and life sciences businesses in the United States and internationally. The company's Display Technologies segment offers glass substrates for flat panel displays, including liquid crystal displays and organic light-emitting diodes that are used in televisions, notebook computers, desktop monitors, tablets, and handheld devices.
Read More
Recent Analyst Ratings
#3 - Allurion Technologies (NYSE:ALUR)
- Upgrades from Top-Ranked Analysts
- 5 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 4 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2.88 (669.7% Upside)
About Allurion Technologies
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Read More
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.2
- Ratings Breakdown
- 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $7.89 (1,253.6% Upside)
About Invivyd
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Read More
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.8
- Ratings Breakdown
- 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $1.27 (80.5% Upside)
About Oatly Group
Oatly Group AB, an oatmilk company, provides a range of plant-based dairy products made from oats in Europe, the Middle East, Africa, the Americas, and Asia. It offers Barista edition oatmilk, oatgurts, frozen desserts, ice-creams, and yogurts; cooking products, including cooking cream, in regular and organic, Crème Fraiche, whipping cream, vanilla custard, and spreads in a variety of flavors; and ready-to-go drinks.
Read More
Recent Analyst Ratings
#6 - Purple Innovation (NASDAQ:PRPL)
- Upgrades from Top-Ranked Analysts
- 4 (in the last 90 days)
- Consensus Rating
- Moderate Buy
- Rating Score
- 2.6
- Ratings Breakdown
- 3 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2.53 (155.1% Upside)
About Purple Innovation
Purple Innovation, Inc designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand.
Read More
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 3 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $3.25 (245.3% Upside)
About Assertio
Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.
Read More
Recent Analyst Ratings
- Upgrades from Top-Ranked Analysts
- 3 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $5.67 (551.3% Upside)
About Ocugen
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Read More
Recent Analyst Ratings
#9 - Taysha Gene Therapies (NASDAQ:TSHA)
- Upgrades from Top-Ranked Analysts
- 3 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $6.63
About Taysha Gene Therapies
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
Read More
Recent Analyst Ratings
#10 - FiscalNote (NYSE:NOTE)
- Upgrades from Top-Ranked Analysts
- 3 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.0
- Ratings Breakdown
- 3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $2.60 (192.1% Upside)
About FiscalNote
FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. The company also delivers that intelligence through its suite of public policy and issues management products, as well as powerful tools to manage workflows, advocacy campaigns, and constituent relationships.
Read More
Recent Analyst Ratings
While no one can say for sure that these will be the ten best penny stocks next year, Wall Street's top analysts are giving them high price targets, "buy" ratings and are telling their clients to acquire shares.
More Investing Slideshows:
